Ming Zhao
Impact in
- Biotechnology top 0.02%
- Cancer Research and Treatments
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
-
- Cancer Research and Treatments 86
-
- Nanoplatforms for cancer theranostics 60
- Co-authors
- Robert M. Hoffman (90 shared papers)Michael Bouvet (44 shared papers)Meng Yang (5 shared papers)Yong Zhang (34 shared papers)Sheldon Penman (4 shared papers)Huaiyu Ma (7 shared papers)Shukuan Li (4 shared papers)Peihong Wu (23 shared papers)
- Journals
- Oncotarget (16 papers)Cell Cycle (13 papers)Cancer Research (8 papers)Journal of Cellular Biochemistry (8 papers)International Journal of Hyperthermia (6 papers)
- Partner nations
- United StatesChinaJapan
In The Last Decade
Ming Zhao
192 papers receiving 6.9k citations
Ming Zhao's Hit Papers
Peers
Comparison fields: 5 of 120
- Biotechnology 3.4k
- Hepatology 1.2k
- Genetics 1.9k
- Biomedical Engineering 2.7k
- Oncology 1.0k
Countries citing papers authored by Ming Zhao
This map shows the geographic impact of Ming Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Zhao more than expected).
Fields of papers citing papers by Ming Zhao
This network shows the impact of papers produced by Ming Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Zhao. The network helps show where Ming Zhao may publish in the future.
Co-authors
The 25 scholars most cited alongside Ming Zhao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 200 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 431 | |
| 2 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion Hit paper breakdown → | 2019 | 388 |
| 3 | 2006 | 267 | |
| 4 | 2007 | 214 | |
| 5 | 2018 | 205 | |
| 6 | 1996 | 167 | |
| 7 | 2021 | 141 | |
| 8 | 2020 | 133 | |
| 9 | 2019 | 133 | |
| 10 | 2008 | 132 | |
| 11 | 2009 | 124 | |
| 12 | 2009 | 120 | |
| 13 | 2009 | 120 | |
| 14 | Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. | 2009 | 117 |
| 15 | 2014 | 111 | |
| 16 | 2009 | 98 | |
| 17 | 2016 | 94 | |
| 18 | 2014 | 93 | |
| 19 | 2010 | 90 | |
| 20 | 2011 | 89 |
About Ming Zhao
Ming Zhao is a scholar working on Biotechnology, Biomedical Engineering, Genetics, Hepatology and Oncology, having authored 200 papers that have together received 7.0k indexed citations. Recurring topics across this work include Cancer Research and Treatments (86 papers), Nanoplatforms for cancer theranostics (60 papers), Virus-based gene therapy research (49 papers), Hepatocellular Carcinoma Treatment and Prognosis (40 papers), Cancer, Hypoxia, and Metabolism (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Mechanisms and Therapy (5 papers). The work is most often cited by research in Biotechnology (3.4k citations), Hepatology (1.2k citations), Genetics (1.9k citations), Biomedical Engineering (2.7k citations) and Oncology (1.0k citations). Ming Zhao has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Robert M. Hoffman, Michael Bouvet, Meng Yang, Yong Zhang, Sheldon Penman, Huaiyu Ma, Shukuan Li, Peihong Wu, Xiaoming Li and Ning Lyu. Their work appears in journals such as Oncotarget, Cell Cycle, Cancer Research, Journal of Cellular Biochemistry and International Journal of Hyperthermia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.